Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2009. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) under the GlaxoSmithKline 2009 Performance Share Plan, approved by shareholders on May 20, 2009.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics for the company. It focuses exclusively on executive compensation details.
- Share Price at Grant (May 28, 2009): Ordinary share price was £10.51; ADS price was $33.50.
- Executive Pricing Adjustment: Awards for Mr. Witty and Mr. Heslop utilized a share price of £10.62 (closing price on May 27, 2009).
- Free Cash Flow Target: The performance target for the cash flow portion of awards is set at £13.5 billion, with maximum vesting at £16 billion.
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It details the establishment of new performance conditions for executive awards effective January 1, 2009.
Guidance, Outlook, and Risks
Performance Conditions:
- Total Shareholder Return (TSR): 60% of awards are contingent on TSR relative to 12 comparator companies (including Abbott, AstraZeneca, Pfizer, etc.). Vesting is 0% below median, 30% at median, and up to 100% in the upper quartile.
- Adjusted Free Cash Flow: 40% of awards are contingent on achieving an Adjusted Free Cash Flow target of £13.5 billion (25% vesting) to £16 billion (100% vesting).
- Performance Periods: Three years (2009–2011) for the Free Cash Flow portion and 50% of the TSR portion; four years (2009–2012) for the remaining 50% of the TSR portion.
Risks and Contingencies:
- Comparator Group Changes: It is anticipated that two companies in the TSR comparator group may be acquired during the performance period, which would reduce the group to 10 companies and adjust the vesting schedule.
- Lapse of Awards: Any portion of an award that does not meet the performance conditions at the end of the period will lapse.
Important Facts for Investors to Verify
- Verify the final composition of the TSR comparator group, as potential acquisitions of two peers may alter the vesting calculations.
- Monitor the company's Adjusted Free Cash Flow performance against the £13.5 billion threshold to determine vesting levels for the cash flow portion of awards.
- Confirm the specific vesting dates, which are determined by the Remuneration Committee following the end of the three and four-year performance periods.
- Note that dividends accrue on the shares during the vesting period but are not included in the share counts listed in the filing.